• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

β-Blocker Therapy After Acute MI

Article

My patient has hypertension, a history of a recent myocardial infarction (MI), and a resting heart rate in the 50s. Which β-blocker is preferred in this setting-or should β-blockers be avoided? -- Edwin Kellerman, MD, Merion Station, Pa

My patient has hypertension, a history of a recent myocardial infarction (MI), and a resting heart rate in the 50s. Which β-blocker is preferred in this setting-or should β-blockers be avoided?
-- Edwin Kellerman, MD,
        Merion Station, Pa

According to American Heart Association/ American College of Cardiology guidelines, all patients who have had an acute MI should receive β-blockers unless they have contraindications to such therapy.1 Contraindications include:
•β-Blocker allergy.
•Bradycardia (heart rate < 60 beats per minute) on day of discharge or day before discharge while not receiving β-blockers.
•Second- or third-degree heart block on ECG on arrival or during hospital stay, in patients without a pacemaker.
I probably would not give this patient a β-blocker unless he is receiving a rate-lowering medication that can be stopped and an alternative drug substituted. If such a substitution can be made, then a β-blocker should be administered for cardioprotection.

In outcomes trials, propranolol, timolol, metoprolol tartrate, acebutolol, and carvedilol reduced cardiovascular mortality.2 Metoprolol tartrate has indications for acute MI and protection up to 3 months. “Although the efficacy of [metoprolol tartrate] beyond 3 months has not been conclusively established, data from studies with other β-blockers suggest that treatment should be continued for 1 to 3 years.”3 Other β-blockers have not shown a protective effect. The Table shows the indications for each of the β-blockers marketed in the United States.

 

-- L. Michael Prisant, MD,
        Professor of Medicine
        Director of Hypertension & Clinical Pharmacology
        Medical College of Georgia
        Augusta

References:

REFERENCES:


1.

Krumholz HM, Anderson JL, Brooks NH, et al. ACC/AHA clinical performance measures for adults with ST-elevation and non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non–ST-Elevation Myocardial Infarction).

Circulation.

2006;113:732-761.

2.

Freemantle N, Cleland J, Young P, et al. β-Blockade after myocardial infarction: systematic review and meta regression analysis.

BMJ.

1999;318:1730-1737.

3.

Lopressor [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
© 2024 MJH Life Sciences

All rights reserved.